Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 2003
[Cost-minimization study on the prescription of intravenous proton pump inhibitors: pantoprazole versus omeprazole].
Сравнительное исследованиеСтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
García González F, Soler Company E, Hedo Aparicio G
Аннотация
OBJECTIVE: To compare and quantify intravenous omeprazole versus intravenous pantoprazole prescription habits in common acid-related diseases such as gastro-esophageal reflux disease, duodenal ulcer, and gastric ulcer.
MATERIAL AND METHODS: We designed an observational, longitudinal prospective and multicenter cost-minimization study to be carried out in Spanish hospitals.
RESULTS: The pantoprazole regimen consisted of 40 mg/day (median), one half of that of omeprazole with 80 mg/day overall for these conditions (p < 0.05). This dosage was significantly different for duodenal ulcer (40.0 +/- 0.0 versus 90.6 +/- 22.5 mg/day, p < 0.05), and gastric ulcer (50.3 +/- 17.8 versus 85.8 +/- 39 mg/day, p < 0.05), but not for gastro-esophageal reflux disease (50.9 +/- 18.7 versus 62.2 +/- 21.1, p > 0.05). Costs for these regimens make treatments using pantoprazole 54% less expensive than treatments using omeprazole. By indication, the cost of duodenal ulcer treatment was 65% less expensive, and that of gastric ulcer 53% less expensive.
CONCLUSIONS: Cost differences amount to approximately one half in treatments using pantoprazole, which is primarily due to the use of doses higher than indicated in treatments using intravenous omeprazole. To reduce expenses stemming from the inadequate use of intravenous proton pump inhibitors the use of pantoprazole is brought forward as a valid option.
MATERIAL AND METHODS: We designed an observational, longitudinal prospective and multicenter cost-minimization study to be carried out in Spanish hospitals.
RESULTS: The pantoprazole regimen consisted of 40 mg/day (median), one half of that of omeprazole with 80 mg/day overall for these conditions (p < 0.05). This dosage was significantly different for duodenal ulcer (40.0 +/- 0.0 versus 90.6 +/- 22.5 mg/day, p < 0.05), and gastric ulcer (50.3 +/- 17.8 versus 85.8 +/- 39 mg/day, p < 0.05), but not for gastro-esophageal reflux disease (50.9 +/- 18.7 versus 62.2 +/- 21.1, p > 0.05). Costs for these regimens make treatments using pantoprazole 54% less expensive than treatments using omeprazole. By indication, the cost of duodenal ulcer treatment was 65% less expensive, and that of gastric ulcer 53% less expensive.
CONCLUSIONS: Cost differences amount to approximately one half in treatments using pantoprazole, which is primarily due to the use of doses higher than indicated in treatments using intravenous omeprazole. To reduce expenses stemming from the inadequate use of intravenous proton pump inhibitors the use of pantoprazole is brought forward as a valid option.